Randomised clinical trial: individualised vs. weight‐based dosing of azathioprine in Crohn's disease

Azathioprine (AZA), a pro‐drug metabolised to the active metabolites 6‐tioguanine nucleotides (6TGN), is a steroid‐sparing therapy for Crohn's disease (CD).

[1]  J. Macdonald,et al.  Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. , 2015, The Cochrane database of systematic reviews.

[2]  J. Sanderson,et al.  Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol. , 2012, Journal of Crohn's & colitis.

[3]  R. Gearry,et al.  Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease , 2011, Inflammatory bowel diseases.

[4]  P. Moayyedi,et al.  An Evidence-Based Systematic Review on Medical Therapies for Inflammatory Bowel Disease , 2011, The American Journal of Gastroenterology.

[5]  T. Dassopoulos,et al.  Thiopurine therapy in inflammatory bowel disease , 2010, Expert review of gastroenterology & hepatology.

[6]  P. Higgins,et al.  Combination of thiopurines and allopurinol: adverse events and clinical benefit in IBD. , 2010, Journal of Crohn's & colitis.

[7]  J. Sanderson,et al.  Low‐dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease , 2010, Alimentary pharmacology & therapeutics.

[8]  C. O'Morain,et al.  The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. , 2010, Journal of Crohn's & colitis.

[9]  M. Schwartz,et al.  Long term efficacy and safety of allopurinol and azathioprine or 6-mercaptopurine in patients with inflammatory bowel disease. , 2009, Journal of Crohn's & colitis.

[10]  M. Cepoiu,et al.  Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. , 2009, The Cochrane database of systematic reviews.

[11]  R. Gearry,et al.  Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[12]  V. Armstrong,et al.  6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease: results from a randomized, controlled, open trial. , 2007, Clinical chemistry.

[13]  S. Hanauer,et al.  Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[14]  J. Lewis,et al.  Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. , 2006, Gastroenterology.

[15]  W. Tremaine,et al.  American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. , 2006, Gastroenterology.

[16]  S. Targan,et al.  6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. , 2002, Gastroenterology.

[17]  B. Bonaz,et al.  Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. , 2000, Gastroenterology.

[18]  E. Seidman,et al.  Chronic intermittent elemental diet improves growth failure in children with Crohn's disease. , 1988, Gastroenterology.